ArticleJB & JS open access
The Immunothrombotic Phenotype: Early Inflammatory and Hematologic Markers that Identify Children at Increased Risk of Avascular Necrosis Following Septic Arthritis.
Article in JB & JS open access. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Avascular necrosis (AVN) is a devastating complication of pediatric septic arthritis (SA). While traditionally attributed to increased intra-articular pressure, emerging evidence suggests that the host's systemic response to infection may contribute to ischemic injury. We hypothesized that an immunocoagulopathic phenotype characterized by extreme inflammation and platelet consumption would identify children at the highest risk of developing AVN. Methods: Following institutional review board approval, children aged younger than 18 years diagnosed with SA between 2010 and 2016 were retrospectively identified from a multicenter database. The primary outcome was the development of AVN. Demographic, clinical, microbiologic, and early laboratory variables were collected. Multivariable logistic regression using Firth's penalized likelihood method was used to account for rare events. Subgroup-level predicted risks of AVN were calculated based on combinations of dichotomized laboratory markers. Results: Among 616 children with SA, 23 developed AVN (incidence, 3.7%). Patients with AVN demonstrated greater early inflammatory burden, including higher C-reactive protein (CRP) levels, lower platelet counts, and more frequent positive blood and tissue cultures. In multivariable analysis, extreme CRP elevation (>160 mg/L) and relative thrombocytopenia (<245 × 10 Conclusions: In this multicenter cohort, AVN occurred in 3.7% of children with SA. The development of AVN was strongly associated with an immunocoagulopathic phenotype, defined by extreme inflammation (CRP >160 mg/L) and coagulopathy (relative thrombocytopenia <245 × 10 Level of Evidence: Level IV, prognostic. See Instructions for Authors for a complete description of levels of evidence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.